Repligen (NASDAQ:RGEN) Coverage Initiated at UBS Group

UBS Group assumed coverage on shares of Repligen (NASDAQ:RGEN) in a research report issued on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $225.00 price target on the biotechnology company’s stock. UBS Group’s price objective suggests a potential upside of 34.63% from the company’s current price.

Several other brokerages have also commented on RGEN. Citigroup raised shares of Repligen to a “buy” rating in a research report on Tuesday, July 7th. Zacks Research raised shares of Repligen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 30th. Wolfe Research began coverage on Repligen in a report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price objective for the company. HSBC cut their target price on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Finally, Royal Bank Of Canada assumed coverage on Repligen in a research report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $168.57.

Repligen Trading Down 0.8%

Repligen stock traded down $1.40 during trading on Wednesday, hitting $167.13. The company’s stock had a trading volume of 35,404 shares, compared to its average volume of 1,012,732. The stock’s fifty day moving average is $156.80 and its 200 day moving average is $134.68. Repligen has a 1-year low of $100.99 and a 1-year high of $188.73. The stock has a market capitalization of $9.43 billion, a price-to-earnings ratio of 228.76, a P/E/G ratio of 3.06 and a beta of 1.05. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The firm had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same period last year, the company earned $0.26 EPS. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, equities research analysts predict that Repligen will post 2.06 EPS for the current year.

Insiders Place Their Bets

In other Repligen news, CFO Jason Garland sold 733 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in RGEN. Engineers Gate Manager LP boosted its stake in shares of Repligen by 146.0% in the second quarter. Engineers Gate Manager LP now owns 7,646 shares of the biotechnology company’s stock valued at $1,043,000 after purchasing an additional 4,538 shares during the period. Waverly Advisors LLC grew its stake in shares of Repligen by 10.1% during the second quarter. Waverly Advisors LLC now owns 32,751 shares of the biotechnology company’s stock valued at $4,469,000 after acquiring an additional 3,009 shares in the last quarter. Nykredit A S purchased a new stake in shares of Repligen during the second quarter worth about $269,000. Corient Private Wealth LP increased its position in shares of Repligen by 420.9% during the second quarter. Corient Private Wealth LP now owns 11,319 shares of the biotechnology company’s stock worth $1,544,000 after acquiring an additional 9,146 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Repligen in the second quarter worth about $1,173,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.